Table 3.

Ongoing clinical trials evaluating beta-blocker therapy in patients with acute myocardial infarction and without reduced ejection fraction

Trial	Country	No. of patients	Inclusion criteria	Primary end-point	Point of patients enrollment	Follow-up period	Expected completion date	Study Ida)
REDUCE	Sweden	5,000	EF ≥50%	All-cause death or nonfatal MI	1–7 Days after MI	3 yr	Dec 1, 2025	NCT03278509
REBOOT	Italy, Spain	8,468	EF >40%	All-cause death, nonfatal MI, or HF	At discharge	3 yr	Nov 1, 2024	NCT03596385
BETAMI	Norway	10,000	EF ≥40%	All-cause death or nonfatal MI	1–8 Days after PCI or thrombolysis	2 yr	Oct 1, 2023	NCT03646357
DANBLOCK	Denmark	3,570	EF ≥40%	All-cause death, nonfatal MI, revascularization, stroke, ventricular arrhythmia, cardiac arrest with successful resuscitation or HF	14 Days after MI	6 mo–6 yr	Jun 1, 2024	NCT03778554
AβYSS	France	3,700	EF ≥40%	All-cause death, stroke, MI, or hospitalization for other CV reason	≥6 Months after MI	4 yr	Aug 1, 2023	NCT03498066
SMART-DECISION	Korea	2,540	EF ≥40%	All-cause death, MI, or hospitalization for HF	After at least 1 year of β-blocker therapy	2.5 yr	Mar 1, 2026	NCT04769362

REDUCE: randomized evaluation of decreased usage of betablocckers after myocardial infarction; REBOOT: treatment with beta-blockers after myocardial infarction without reduced ejection fraction; BETAMI: betablocker treatment after acute myocardial infarction in patients without reduced left ventricular systolic function; DANBLOCK: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction; AβYSS: assessment of βeta blocker interruption after uncomplicated myocardial infarction on safety and symptomatic cardiac events requiring hospitalization; SMART-DECISION: discontinuation of β-blocker therapy in stabilized patients after acute myocardial infarction; EF: ejection fraction; MI: myocardial infarction; HF: heart failure; PCI: percutaneous coronary intervention; CV: cardiovascular.

^a)Study identification number enrolled in ClinicalTrials.gov.